According to TipRanks.com, Kaminski is a 1-star analyst with an average return of -7.3% and a 37.5% success rate. Kaminski covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Dyne Therapeutics, and Lumos Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Krystal Biotech with a $108.33 average price target, which is a 41.7% upside from current levels. In a report released today, William Blair also maintained a Buy rating on the stock.
Based on Krystal Biotech’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $10.38 million. In comparison, last year the company had a GAAP net loss of $5.36 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.